What It Looks Like on the Street
You come in on day one hurting bad from the poly-dope — fentanyl mixed with benzos and xylazine. You're scared but clear enough to understand the risks and benefits. You listen, you ask questions, and you give real informed consent to start the hydromorphone script. On paper, that consent looks solid.
By day three the benzo and xylazine layers have hit hard. You're not sleeping, you're agitated, maybe sliding into delirium or psychosis. Your mind is completely different from the person who gave consent on day one. You can't think straight, you can't re-evaluate whether this is still the right path, and you can't meaningfully decide to stay, adjust, or pull out.
The program only really fixed the opioid part. The other two systems are still screaming, so many people start chipping with street dope again just to function.
Where Levy's Framework Breaks Down
Neil Levy's 2015 paper "Addiction, Autonomy, and Informed Consent: On and Off the Garden Path" is often used to defend this kind of program. He argues that addiction isn't true compulsion and that addicts can still say "no" to drugs under the right conditions.
But here's the hole when we look at today's poly-dope reality: You give real consent at the start and it still doesn't protect you. Levy assumes the program will hold stable conditions throughout. Continuing consent in medical ethics was never designed for a situation where the treatment itself destabilizes your capacity so quickly.
By day three the benzo and xylazine layers have changed your cognitive state so fast that day-one-you and day-three-you are night and day. The impairment isn't pre-existing — it's produced by the program's own gaps in managing the full poly-dope withdrawal.
Nobody Is Measuring This
One of the biggest problems is that we don't even have good numbers on this. Program evaluations mostly track opioid outcomes, overdoses, retention rates, and self-reported street drug use. The benzo and xylazine withdrawal stuff — the delirium, psychosis, the way your head can completely change in a few days — barely shows up in the official data.
That knowledge lives mostly in what people who've been through it tell each other. I filed a Freedom of Information request on March 22nd trying to get real numbers on exactly this. The lack of tracking isn't proof it isn't happening. It's proof nobody's looking closely enough.
There's almost no published information linking informed consent to poly-dope because most studies still treat safer supply as if the main issue is just opioids.
The Economic Harm Rolls On
Because we're not measuring how often this collapse actually happens, the economic harm keeps rolling on unchecked. The hydros only partly stabilize you, so many people keep chipping with street dope.
At the same time, the flood of take-home Dilaudids has crashed the street price in Ontario, from $15–20 down to $1–2 or less. In Ottawa, right beside Quebec where safer supply is much more limited, that creates easy arbitrage: pills move across the border for higher value, cash or fentanyl comes back.
Instead of helping people exit the game, the model can keep them half-in it, still hustling, still dependent on the street economy to fill the gaps the program doesn't touch.
What Actually Working Looks Like
I support harm reduction that actually works. That means programs have to manage all three systems from the start and treat consent as an ongoing process instead of a one-and-done formality.
Until we close that gap between the theory and the street, we're not giving people real autonomy. We're just giving them a safer way to stay stuck, while the government gets to look busy.
If you work in harm reduction, policy, or ethics and want to discuss consent, autonomy, or whether the contaminated drug supply changes how we think about informed consent to bodily harm in Canada, I'd like to hear from you. There's practically no literature on this yet and that needs to change. Get in touch.